机构：[a]Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China外科系统神经外科江苏省人民医院[b]Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 02115, USA[c]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院
GBM tissues are comprised of not only tumor cells but also tumor-associated nontumor cells, such as stromal cells and immune cells, which dilute the purity of glioma cells and function in glioma biology. However, the roles of miRNAs in modulating glioma purity are not clari?ed. In total, 838 glioma samples with transcriptome data, including 537 RNAseq data from TCGA project and 301 microarray data from Chinese Glioma Genome Atlas (CGGA project), were recruited into our investigation. Tumor purity, molecular subtypes and IDH status were also available. R language was employed as the main tool for statistical analysis and graphical work. Screening miRNA profiling and paired TCGA samples' transcriptome data demonstrates that miR-17-5p expression harbors the most significant positive correlation with glioma purity among all miRNAs. CXCL14 shows robust negative correlation with miR-17-5p expression in TCGA and CGGA dataset. miR-17-5p directly targets CXCL14 and functions as a tumor-suppressor of GBM. CXCL14 showed lower expression in proneural subtype and may contribute as a potential marker for proneural subtype in glioma. Genes markedly correlated with CXCL14 are involved in essential functions associated with anti-tumor immune process. CXCL14 has a strong correlation with immune(T cells, Monocytic lineage and Neutrophils) and Fibroblasts within glioma environment. miR-17-5p and CXCL14 exhibited predictive values for high-grade glioma(HGG) patients: Higher miR-17-5p indicated significantly longer survival while lower CXCL14 indicated longer survival. Our results highlight the importance of the miR-17-5p-CXCL14 axis in regulating key steps of anti-tumor immune process and may serve as potential targets of immune treatments for gliomas.
基金：
This work was supported by a grant from the National Natural Science Foundation of China (No. 81402056 and 81472362), National High Technology Research, Development Program of China (863) (No.2012AA02A508) and the National Key Research and Development Plan (No. 2016YFC0902500).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|1 区医学
小类|2 区免疫学2 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|2 区免疫学2 区肿瘤学
第一作者：
第一作者机构：[a]Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China[b]Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 02115, USA
共同第一作者：
通讯作者：
通讯机构：[a]Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China[*1]Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, No.300, Guangzhou Road, Gulou District, Nanjing, 210029, PR China[*2]Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, No.300, Guangzhou Road, Gulou District, Nanjing, 210029, PR China
推荐引用方式(GB/T 7714)：
Ailiang Zeng,Jianxin Yin,Zheng Wang,et al.miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas[J].ONCOIMMUNOLOGY.2018,7(12):-.doi:10.1080/2162402X.2018.1510277.
APA：
Ailiang Zeng,Jianxin Yin,Zheng Wang,Chuanbao Zhang,Rui Li...&Yongping You.(2018).miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas.ONCOIMMUNOLOGY,7,(12)
MLA：
Ailiang Zeng,et al."miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas".ONCOIMMUNOLOGY 7..12(2018):-
医学